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Lung injury resulting from inhalation of smoke or chemical products of combustion continues to be associated
with significant morbidity and mortality. Combined with cutaneous burns, inhalation injury increases fluid
resuscitation requirements, incidence of pulmonary complications and overall mortality of thermal injury. While
many products and techniques have been developed to manage cutaneous thermal trauma, relatively few
diagnosis-specific therapeutic options have been identified for patients with inhalation injury. Several factors explain
slower progress for improvement in management of patients with inhalation injury. Inhalation injury is a more
complex clinical problem. Burned cutaneous tissue may be excised and replaced with skin grafts. Injured pulmonary
tissue must be protected from secondary injury due to resuscitation, mechanical ventilation and infection while
host repair mechanisms receive appropriate support. Many of the consequences of smoke inhalation result from an
inflammatory response involving mediators whose number and role remain incompletely understood despite
improved tools for processing of clinical material. Improvements in mortality from inhalation injury are mostly due
to widespread improvements in critical care rather than focused interventions for smoke inhalation.
Morbidity associated with inhalation injury is produced by heat exposure and inhaled toxins. Management of toxin
exposure in smoke inhalation remains controversial, particularly as related to carbon monoxide and cyanide.
Hyperbaric oxygen treatment has been evaluated in multiple trials to manage neurologic sequelae of carbon
monoxide exposure. Unfortunately, data to date do not support application of hyperbaric oxygen in this population
outside the context of clinical trials. Cyanide is another toxin produced by combustion of natural or synthetic
materials. A number of antidote strategies have been evaluated to address tissue hypoxia associated with cyanide
exposure. Data from European centers supports application of specific antidotes for cyanide toxicity. Consistent
international support for this therapy is lacking. Even diagnostic criteria are not consistently applied though
bronchoscopy is one diagnostic and therapeutic tool. Medical strategies under investigation for specific treatment
of smoke inhalation include beta-agonists, pulmonary blood flow modifiers, anticoagulants and antiinflammatory
strategies. Until the value of these and other approaches is confirmed, however, the clinical approach to inhalation
injury is supportive.
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Respiratory injury resulting from inhalation of smoke or
chemical products of combustion is associated with
significant morbidity and mortality. Even in isolation,
inhalation injury can be associated with longstanding
pulmonary dysfunction [1]. Combined with cutaneous
burns, inhalation injury increases fluid resuscitation* Correspondence: David.J.Dries@HealthPartners.com
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distribution, and reproduction in any mediumrequirements, incidence of pulmonary complications and
overall mortality of thermal injury. Unfortunately, a con-
sistent diagnostic strategy is unavailable and treatment is
largely supportive [2-4]. We will review pathology, diag-
nostic options and medication strategies.
The classic paper describing the effects of inhalation
injury, and its principle complication, pneumonia, on
mortality in burn patients comes from Shirani, Pruitt,
Mason, and the U.S. Army Institute of Surgical Research
in San Antonio, Texas [5]. A review of over 1,000 pa-
tients was conducted, in which data were gathered ontral Ltd. This is an Open Access article distributed under the terms of the
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ment of pneumonia during hospitalization. Patients at
risk for inhalation injury were investigated by bronchos-
copy, Xenon lung scans, or both. The diagnosis of inhal-
ation injury was made in 373 patients. With increasing
burn size, there was a corresponding rise in the inci-
dence of inhalation injury. The diagnosis of pneumonia
was made at approximately 10 days for patients experi-
encing this complication along with inhalation injury.
Three dimensional plots were constructed to demon-
strate the incremental mortality of inhalation injury and
inhalation injury when complicated by pneumonia on
patients in this population. Expected mortality increased
by a maximum of 20% in the presence of inhalation
injury alone and 60% when both inhalation injury and
pneumonia were present. The contributions of inhal-
ation injury and pneumonia to mortality were found to
be independent and additive. Expected mortality in pa-
tients with very small or very large burns was not af-
fected by these pulmonary complications except at the
extremes of age (Figures 1, 2 and 3).
Two other papers support the observations of Shirani
and coworkers. A more recent meta-analysis on prog-
nostic factors in burn injury with smoke inhalation re-
veals that overall mortality increased dramatically with
inhalation injury (27.6% versus 13.9%). Extent of burn
size and age were predictive of mortality. Another study
included a predictive model of outcome with cutaneous
injury plus smoke inhalation. In a review of 110 pa-
tients, percent Total Body Surface Area (TBSA) cutane-
ous injury, age and PaO2/FiO2 ratio were mortality
predictors [6-8].
While many products and techniques have been devel-
oped to manage cutaneous injury, relatively few diagnosis-
specific therapeutic options have been identified for
patients with inhalation injury. Improvements in mortality























Figure 1 Relationship between burn size and incidence of inhalation
increasing burn size [5].improvements in critical care rather than focused inter-
ventions for smoke inhalation. In fact, one consensus
statement indicates that treatment of inhalation injury has
not kept pace with improvements in the care of cutaneous
burns [9].
A variety of factors explain slower progress for im-
provement in management of inhalation injury. Burned
cutaneous tissue may be excised and replaced with skin
grafts, but njured pulmonary tissue must merely be sup-
ported and protected from secondary injury. The critic-
ally ill burn patient has multiple mechanisms in addition
to smoke inhalation that may contribute to lung injury
such as sepsis, Ventilator-Induced Lung Injury (VILI) or
a systemic inflammation in response to burns. Thus,
inhalation injury has a significant effect on burn patient
outcome but is difficult to separate from the contribu-
tion of other mechanisms which also affect the lungs
[2,10,11].
A significant limitation for clinicians studying smoke
inhalation has been the lack of uniform criteria for diag-
nosis of inhalation injury, scaling its severity and identi-
fying a common terminology to describe outcomes [2,9].
Thus, comparative studies are difficult to evaluate. Some
practitioners describe patients requiring intubation and
mechanical ventilation after smoke inhalation. Other
studies emphasize nuclear medicine scans for the meta-
bolic diagnosis of inhalation injury. Multicenter trials
have the confounding impact of differing local defini-
tions of inhalation injury. The need for standardized
diagnostic criteria and a quantifying system for inhal-
ation injury have been recognized in the burn literature
for many years.
Anatomy and physiology of inhalation injury
Inhalation injury may describe pulmonary trauma caused
by inhalation of thermal or chemical irritants. Anatomic-
ally, injuries are divided into three classes: 1) heat injury45 55 65 75 85 95
an Burn Size
y and Burn Size
injury illustrates the rise in occurrence of inhalation injury with
Figure 2 Burn size as percentage of total body surface area on X axis, age on Y axis, and percent increment in mortality due to the
presence of inhalation injury on Z axis are shown. Mortality, in the presence of inhalation injury alone, rose by a maximum of approximately
20% in patients in midrange of severity of injury as indexed by age and burn size [5].
Dries and Endorf Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2013, 21:31 Page 3 of 15
http://www.sjtrem.com/content/21/1/31which is restricted to upper airway structures except in
the case of steam jet exposure, 2) local chemical irritation
throughout the respiratory tract and 3) systemic toxicity
as may occur with inhalation of carbon monoxide or
cyanide [3].
Heat injury to the upper airway
Air temperature in a room containing a fire reaches
1000°F. Because of the combination of efficient heat dis-
sipation in the upper airway, low heat capacity of air and
reflex closure of the larynx, super-heated air usually
causes injury only to airway structures above the carina.
Injury to these airway structures may cause massive
swelling of the tongue, epiglottis, and aryeepiglottic folds
with obstruction. Airway swelling develops over a matter
of hours as fluid resuscitation is ongoing. Initial evalu-
ation is not a good indicator of the severity of obstruc-
tion that may occur later [3,12].Figure 3 Burn size as percentage of total body surface area on X axis
shown. Mortality rose by a maximum of approximately 60% in patients in
pneumonia were present [5].Respiratory status must be continuously monitored to
assess the need for airway control and ventilator sup-
port. If history and initial examination cause suspicion
of significant thermal injury to the upper airway, intub-
ation for airway protection should be considered.
Chemical injury to the lower airway
Most substances when burned, generate material toxic
to the respiratory tract [2,3,9]. Burning rubber and plas-
tic produces sulfur dioxide, nitrogen dioxide, ammonia
and chlorine with strong acids and alkali when com-
bined with water in the airways and alveoli. Laminated
furniture contains glues and wall paneling also may re-
lease cyanide gas when burned. Burning cotton or wool
produces toxic aldehydes. Smoke-related toxins damage
epithelial and capillary endothelial cells of the airway.
Histologic changes resemble tracheobronchitis. Mucociliary
transport is destroyed and bacterial clearance reduced., age on Y axis, and percent increment in mortality on Z axis are
midrange of age and burn size when both inhalation injury and
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loss. Alveolar macrophages are stressed leading to inflam-
matory response with chemotaxins. Early inflammatory
changes occurring in the airway are followed by a period of
diffuse exudate formation. Bronchiolar edema may become
severe. A combination of necrotizing bronchitis, bronchial
swelling, and bronchospasm causes obstruction of large
and small airways. Wheezing occurs with bronchial swelling
and irritant receptor stimulation. Increased capillary perme-
ability magnifies airway and pulmonary edema [13-15].
Respiratory failure may occur from 12 to 48 hours after
smoke exposure. Characteristics are decreased lung com-
pliance, increased ventilation perfusion mismatch, and in-
crease in dead space ventilation. Injury may progress to
mucosal sloughing and intrapulmonary hemorrhage with
mechanical obstruction of lower airways and flooding of
alveoli [16,17]. Because of necrosis of respiratory epithe-
lium, patients are predisposed to secondary bacterial inva-
sion and superimposed bacterial pneumonia [5]. Recovery
may require several months [18].
Carbon monoxide and cyanide exposure
Carbon monoxide is an odorless, tasteless, nonirritating
gas produced by incomplete combustion. Carbon mon-
oxide poisoning is a major source of early morbidity in
burn-injured patients with many fatalities occurring at
the scene of the fire due to this mechanism. Carboxy-
hemoglobin levels exceed 10% in a closed space fire.
Significant injury may occur in a short period of time
with the exposure with as little as 10% carboxyhemoglo-
bin [3,19].
The affinity of carbon monoxide for hemoglobin is 200
times greater than for oxygen. Carbon monoxide competesFigure 4 Hemoglobin is converted rapidly to carboxyhemoglobin in twith oxygen for hemoglobin binding which shifts the oxy-
hemoglobin dissociation curve to the left and alters its
shape. Oxygen delivery to tissues is compromised because
of reduced oxygen carrying capacity of the blood and less
efficient dissociation at the tissue level. Carbon monoxide
competitively inhibits intracellular cytochrome oxidase en-
zyme systems, most notably cytochrome P-450 resulting in
inability of cellular systems to utilize oxygen (Figures 4 and
5) [20,21].
Inhaled hydrogen cyanide, produced during combus-
tion of multiple household materials, also inhibits the
cytochrome oxidase system and may have a synergistic
effect with carbon monoxide producing tissue hypoxia
and acidosis as well as a decrease in cerebral oxygen
consumption [3,21].
Carbon monoxide poisoning may be difficult to detect.
The absorbent spectrum of carboxyhemoglobin and oxy-
hemoglobin are very similar and pulse oximeters cannot
distinguish between the two forms of hemoglobin. The
PaO2 measure from an arterial blood gas reflects the
amount of oxygen dissolved in plasma but does not
quantitate hemoglobin saturation, the most important
determinant of oxygen carrying capacity of the blood.
Carboxyhemoglobin levels may be measured directly but
this test is rarely available at the incident scene. Because
of the inevitable delay between smoke exposure and
carboxyhemoglobin testing, levels measured on arrival at
a healthcare facility do not reflect the true extent of in-
toxication [3,22,23].
Half-life of carboxyhemoglobin is 250 minutes for the
victim breathing room air. This is reduced to 40 to 60 -
minutes with inhalation of 100% oxygen [3,15]. While
hyperbaric oxygenation will further reduce the half-lifehe presence of carbon monoxide [3].
Figure 5 Carboxyhemoglobin-induced changes in the oxygen-hemoglobin dissociation curve. Oxygen-carrying capacity is markedly
diminished when carboxyhemoglobin values reach 40% to 50%. In addition, the leftward displacement of the oxygen-hemoglobin dissociation
curve makes the oxygen that is bound to hemoglobin less available for delivery to tissues [3].
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cult environment in which to monitor the patient, per-
form fluid resuscitation, and provide initial burn care.
Patients with the greatest need for hyperbaric oxygen
therapy are frequently the most difficult to manage in
this environment [24].
Diagnosis of inhalation injury
For the clinician, the diagnosis of inhalation injury is a
somewhat subjective decision based largely on a history
of smoke exposure in a closed space. Physical findings
including facial injury, singed nasal hairs, soot in the
proximal airways, carbonaceous sputum production and
changes in voice may help support the diagnosis
[2,3,9,22]. These findings may be confirmed by diagnos-
tic studies including fiberoptic bronchoscopy, typically
performed within 24 hours of admission [25]. History in-
cludes mechanisms of exposure such as flame, electri-
city, blast injury, steam or hot liquid, quality of inhaled
irritants (house fire or industrial toxins) and duration of
exposure with further complications caused by loss of
consciousness or physical disability. Physical examin-
ation may include findings such as visible injury to the
respiratory tract, airway edema or evidence of pulmon-
ary parenchymal damage and dysfunction.
Diagnostic criteria for inhalation injury are compli-
cated by heterogeneous presentation and distinguishing
between exposure to inhaled irritants and injury basedon heated gas exposure [9,26]. Progressive respiratory
failure may not be directly proportional to the degree of
smoke exposure. Such differences are likely due to com-
position of inhaled materials and differences in host
response.
Multiple burn centers have demonstrated that patients
with inhalation and burn injuries require increased fluid
volumes during immediate resuscitation when compared
to individuals with burn injury alone [4,9,27]. Changes
in lung compliance and airway resistance have also been
proposed as predictors of outcome and scales for sever-
ity of inhalation injury. Scoring systems, based on bron-
choscopic evaluation, have been used for inhalation
injury and attempts to identify the relationship of this
data to the development of Acute Respiratory Distress
Syndrome have been made. Endorf and Gamelli, in re-
cent work, examine the degree of inhalation injury,
PaO2/FiO2 ratio, and effects on fluid requirements dur-
ing acute resuscitation. Table 1 demonstrates a typical
set of bronchoscopic criteria for grading of inhalation
injury [25].
These workers reviewed 80 patients from a single cen-
ter with suspected inhalation injury requiring intubation,
mechanical ventilation, and fiberoptic bronchoscopy dur-
ing the first 24 hours of hospitalization. Details of burn
injury were collected and patients categorized according
to a bronchoscopic grading system. Pulmonary mechanics
and gas exchange were examined at regular intervals
Table 1 Bronchoscopic criteria used to grade inhalation
injury
Grade 0 (No Injury): Absence of carbonaceous deposits,
erythema, edema, bronchorrhea, or
obstruction.
Grade 1 (Mild Injury): Minor or patchy areas of erythema,
carbonaceous deposits in proximal or
distal bronchi. [any or combination]
Grade 2 (Moderate
Injury):
Moderate degree of erythema,
carbonaceous deposits, bronchorrhea,
with or without compromise of the
bronchi.
[any or combination]






Evidence of mucosal sloughing, necrosis,
endoluminal obliteration. [any or
combination]
Endorf and Gamelli [25].
Reproduced with permission from J Burn Care Res and Endorf, et al.
Table 3 Comparison by P:F ratio
P:F <350 P:F >350 P
Value(30 Patients) (30 Patients)
mL/kg/%TBSA 7.4 (±0.4) 5.9 (±0.5) .03
Ventilator days 12.2 (±2.4) 0.9 (±1.5) .21
Survival 18 (60%) 23 (77%) .17
Endorf and Gamelli [25].
Reproduced with permission from J Burn Care Res and Endorf, et al.
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fluid volume infused was noted for the first 48 hours after
burn injury [25].
Patients with more severe bronchoscopic injury on
initial bronchoscopy (Grades 2, 3, 4) had significantly
worse survival than patients with bronchoscopic Grades
0 or 1 (p = 0.03). Contrary to reports of other investiga-
tors, these workers noted that high-grade bronchoscopic
findings were not associated with increased fluid require-
ments. Initial pulmonary compliance also did not correlate
with acute fluid requirements. Notably, patients with a
PaO2/FiO2 ratio <350 at presentation had a statistically sig-
nificant increase in fluid resuscitation requirement com-
pared with patients having a PaO2/FiO2 ratio >350 (p =
0.03) (Tables 2 and 3).
Most writers agree that a consensus regarding the
diagnosis of inhalation injury will be based on modalities
which are widely available and do not require highly spe-
cialized skills. A consistent vocabulary for description ofTable 2 Comparison for bronchoscopic grade of
inhalation injury
Group 1 Group 2 P
Value(Grades 0 and 1) (Grades 2, 3, 4)
25 Patients 35 Patients
mL/kg/%TBSA 6.6 (±0.7) 6.7 (±0.4) .88
Ventilator days 8.6 (±1.4) 12.8 (±2.2) .11
Survival 21 (84%) 20 (57%) .03
Initial compliance 49.9 (±4.4) 49.7 (±3.1) .98
Initial P:F Ratio 371.5 (±32) 329.7 (±29) .33
Endorf and Gamelli [25].
Reproduced with permission from J Burn Care Res and Endorf, et al.injury and its physiologic effects is also required along
with reliable description of the composition and dispos-
ition of inhaled irritants with some grading of intensity
of exposure [28].
The best tools presently available for diagnosis of inhal-
ation injury are clinical presentation and bronchoscopic
findings. Difficulty comes with attempts to predict which
patients are vulnerable to resuscitation complications, in-
creased pulmonary dysfunction, respiratory failure and
mortality. Attempts to identify prognostic factors for pa-
tients with smoke inhalation have been made. It has been
difficult to identify reliable indicators of progressive respira-
tory failure in patients with smoke inhalation. Moreover,
proximal injury observed by bronchoscopy is frequently
greater than peripheral pulmonary parenchymal injury. Sev-
eral investigative teams show lack of correlation between
severity of bronchoscopic findings, fluid resuscitation re-
quirements, development of Acute Respiratory Distress
Syndrome (ARDS) and other clinical outcomes [25,28-31].
Other diagnostic modalities such as 99-technetium scan-
ning and xenon scanning may confirm inhalation injury
but due to logistical reasons are not widely used in the ini-
tial evaluation of smoke inhalation [32].
Treatment strategies
Bronchoscopy
In many centers, bronchoscopy has a role limited to
obtaining lavage fluid for culture and assessing the de-
gree of airway injury which may predict outcome [33].
Severe inhalation injury is in part a mechanical process
characterized by pulmonary edema, bronchial edema,
and secretions, can occlude the airway leading to atelec-
tasis and pneumonia. Aggressive use of bronchoscopy is
highly effective in removing foreign particles and accu-
mulated secretions that worsen the inflammatory re-
sponse and may impede ventilation [34,35]. While it
seems intuitive that bronchoscopy could improve pul-
monary hygiene and outcomes by removing secretions
and epithelial slough in burn patients, only recently has
this question been addressed by a review of the National
Burn Repository of the American Burn Association [33].
Carr and coworkers reviewed the National Burn Reposi-
tory from 1998 to 2007 to determine outcome differences
in burn patients with inhalation injury and pneumonia
who did and did not receive bronchoscopy [33]. Patients
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monia who underwent bronchoscopy had a decreased
duration of mechanical ventilation compared to patients
who did not have bronchoscopy. Patients with larger in-
juries and pneumonia did not have improved outcomes
with bronchoscopy. When patients having at least one
bronchoscopy procedure were compared with those who
did not undergo bronchoscopy, the patients receiving this
test had a shorter length of intensive care unit and hos-
pital stay. Hospital charges were higher in patients who
did not undergo bronchoscopy compared with those who
received this procedure. When compared with patients
who did not undergo bronchoscopy, patients who did
have one or more bronchoscopic procedures had a re-
duced risk of death by 18%. However, while strong trends
were present, the mortality benefit associated with bron-
choscopy and the reduction in hospital cost represented
trends which did not reach statistical significance.
Carbon monoxide toxicity
Morbidity and mortality associated with carbon mon-
oxide toxicity are the result of hypoxic states associated
with interference with oxygen transport at the cellular
level and compromise of electron transport within
cells. Other potential mechanisms include binding to
myoglobin or hepatic cytochromes and peroxidation of
cerebral lipids. The extent of injury is dependent on the
concentration of carbon monoxide, duration of expos-
ure and underlying health status of the exposed individ-
ual [36,37].
Short- and long-term morbidity of carbon monoxide
toxicity involves neurologic and vascular consequences.
Neurologic sequelae are divided into two syndromes: 1)
persistent neurologic sequelae and 2) delayed neurologic
sequelae. Persistent neurologic sequelae involve neuro-
logic deficits occurring after carbon monoxide exposure
that may improve over time. Delayed neurologic sequelae
is a relapse of neurologic signs and symptoms after a
transient period of improvement. Distinguishing between
these conditions may be difficult. Symptoms of chronic
carbon monoxide toxicity may include fatigue, affective
conditions, emotional distress, memory deficits, difficulty
working, sleep disturbances, vertigo, neuropathy, pares-
thesias, recurrent infections, polycythemia, abdominal
pain and diarrhea [37-39].
Neuropsychological sequelae are common after carbon
monoxide poisoning. In some trials, 40% of involved pa-
tients treated with normobaric oxygen had cognitive se-
quelae when evaluated six weeks after carbon monoxide
exposure and a similar number had affective sequelae.
Other potential consequences include gait and motor
disturbances, peripheral neuropathy, hearing loss and
vestibular abnormalities, dementia and psychosis. These
changes may be permanent [37,40-42].Immediate management of carbon monoxide toxicity
is administration of normobaric oxygen by means of a
nonrebreather reservoir facemask supplied with high
flow oxygen or 100% oxygen by means of an artificial
airway. Administration of normobaric oxygen hastens
elimination of carbon monoxide but one trial did not
show reduction in cognitive sequelae after inhalation of
normobaric oxygen as compared with no supplemental
oxygen therapy [36,37]. Since normobaric oxygen is safe,
readily available and inexpensive, however, it should be
provided until a carboxyhemoglobin level is less than 5%.
Initial support of the exposed patient should emphasize
adequate ventilation and perfusion, neurologic examin-
ation, exposure history and measurement of arterial blood
gases by co-oximetry to assess gas exchange, metabolic
status and carboxyhemoglobin level. A carboxyhemoglo-
bin level greater than 3% in nonsmokers or greater than
10% in smokers confirms exposure to carbon monoxide.
The carbon monoxide level does not correlate with the
presence or absence of initial symptoms or with later out-
comes [35,43,44].
Carbon monoxide exposure can exacerbate angina and
cause cardiac injury even in persons with normal coron-
ary arteries. Thus, exposed patients may require cardio-
vascular investigation including electrocardiogram and
measurement of cardiac enzymes. If cardiac injury is
present, cardiology consultation should be considered
[37,45,46].
The use of hyperbaric oxygen has been advocated to
treat carbon monoxide exposure under the hypothesis that
rapid displacement of carbon monoxide from hemoglobin
at 100% oxygen using hyperbaric pressures will reduce
duration of the cellular hypoxic state [36,37]. Use of
hyperbaric oxygen results in more rapid displacement of
carbon monoxide. Absolute indications and outcomes for
hyperbaric oxygen remain controversial because of lack of
correlation between the only available diagnostic tool,
carboxyhemoglobin levels, and the severity of the clinical
state and outcomes of the initial insult or therapies [36].
In addition, there is no standard for duration or intensity
of hyperbaric oxygen therapy. Hyperbaric oxygen has
potential complications including barotrauma, tympanic
membrane disruption, seizures and air embolism [47-50].
Among published clinical trials of hyperbaric oxygen
therapy, few satisfy all consolidated standards for the
reporting of trials guidelines including double-blinding,
enrollment of all eligible patients, a priori definitions of
outcomes and high rates of follow-up [37,49,51,52]. One
single center prospective trial showed that the incidence
of cognitive sequelae was lower among patients who
underwent three hyperbaric oxygen sessions (initial ses-
sion of 150 minutes, followed by two sessions of 120 -
minutes each, separated by an interval of 6 to 12 hours)
within 24 hours after acute carbon monoxide poisoning
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(25% versus 46%, p = 0.007 and p = 0.03 after adjustment
for cerebellar dysfunction and stratification). Use of hyper-
baric oxygen in this trial reduced the rate of cognitive se-
quelae at 12 months (18% versus 33% with normobaric
oxygen; p = 0.04). This trial did not, however, clearly iden-
tify subgroups of patients in whom hyperbaric oxygen was
more or less beneficial [37].
A Cochrane review of six trials including two published
in abstract form did not support the use of hyperbaric oxy-
gen for patients with carbon monoxide poisoning [53]. A
more recent Cochrane review also failed to demonstrate
convincing benefit from hyperbaric oxygen therapy [54].
However, multiple flaws in the reviewed trials were identi-
fied [36,37]. The use of hyperbaric oxygen therapy for car-
bon monoxide victims continues to be guided by standards
of the community rather than scientific consensus.
Patients with carbon monoxide poisoning should be
followed medically after discharge. Extent and rate of re-
covery after poisoning are variable and recovery is often
complicated by sequelae which can persist after expos-
ure or develop weeks after poisoning and which may be
permanent. Specific therapy for sequelae after carbon
monoxide exposure is not available. Patients with seque-
lae should have symptoms addressed through cognitive,
psychiatric, vocational, speech, occupational and physical
rehabilitation. Data on these interventions in patients
with carbon monoxide sequelae are lacking [37,40].
An important trial examined long-term outcomes of
patients with acute carbon monoxide poisoning [55].
Over 1,000 patients treated over a 30 year period were
examined. Patients studied were treated with hyperbaric
oxygen and survived the acute poisoning episode. Long-
term mortality was compared to a standard population.
Survivors of acute carbon monoxide poisoning experi-
enced excess mortality in comparison to the general popu-
lation. Excess mortality was highest in the group initially
treated for intentional carbon monoxide poisoning. For
the entire group, major causes of death were mental and
psychiatric disorders, injuries and violence. Other more
specific causes of death were alcoholism, motor vehicle
crash with pedestrians, motor vehicle crashes of unspeci-
fied type, accidental poisoning and intentional self-harm.
Consistent with data mentioned above, no difference in
survival was observed by measure of carbon monoxide
poisoning severity after controlling for age, gender, race
and intent of carbon monoxide poisoning.
Cyanide toxicity
Cyanide is produced by combustion of natural or syn-
thetic household materials including synthetic polymers,
polyacrylonitrile, paper, polyurethane, melamine, wool,
horsehair and silk [56,57]. Cyanide can be detected in
trace amounts in smoke at house fires and in the bloodof smokers and fire victims. Ingestion of cyanide prod-
ucts produces metabolic acidosis which is also seen in
burn patients during resuscitation. Cyanide is a normal
human metabolite which the body can detoxify. Cyanide
can be produced in vitro by normal human blood and in
situ in certain organs after death. Much of the interest
in cyanide as a toxin related to inhalation injury stems
from the availability of a cyanide antidote kit.
Barillo recently reviewed the evidence regarding test-
ing of smoke inhalation victims for cyanide [57,58]. Un-
fortunately, a simple and rapid blood assay for cyanide is
lacking and may be of limited utility as cyanide is an
intracellular toxin. As noted above, cyanide is a normal
metabolite in humans and can be produced and de-
graded in blood samples in vitro. Erythrocytes convert
thiocyanate to cyanide in vitro and because blood cyan-
ide is mainly bound to erythrocytes, autolysis of red
blood cells may elevate blood cyanide levels. In normal
individuals, blood cyanide levels range from up to 0.3 mg/
L in nonsmokers to 0.5 mg/L in smokers. Firefighters, des-
pite chronic smoke exposure, have relatively normal blood
cyanide levels. Cyanide is mildly elevated in both fire sur-
vivors and fire fatalities. Survival with blood cyanide levels
of 7–9 mg/L has been documented after cyanide ingestion
or inhalation. Recommendations for treatment of cyanide
intoxication in smoke victims are extrapolated from lim-
ited industrial experience or from suicide and homicide
victims. Overt cyanide poisoning is uncommon and little
human data is available [57,59].
A popular cyanide antidote kit utilizes a series of reac-
tions with oxidation of hemoglobin to methemoglobin
which binds cyanide forming cyanomethemoglobin [60,61].
As cyanomethemoglobin dissociates, free cyanide is
converted to thiocyanate by hepatic mitochondrial en-
zymes using colloidal sulfate or thiosulfate. Thiocyanate
is then excreted in the urine. Despite popularity of the
cyanide antidote kit, documented effectiveness is limited
[57,58,62]. Notably, a methemoglobin level of 20-30% is
required to optimally bind cyanide. Additionally, this is
contraindicated in patients with concurrent carbon
monoxide poisoning as the conversion of carboxyhemo-
globin to methemoglobin may exacerbate hypoxia. An-
other management strategy utilizes sodium thiosulfate
as a substrate in conversion of cyanide to thiocyanate
and is reported to be an effective antidote when used
with or without nitrite. Prospective trials utilizing this
strategy are lacking apart from case studies. Administra-
tion at recommended doses is without serious side ef-
fects while nausea, retching and vomiting have been
reported [57,63].
European data suggests treatment of cyanide poison-
ing with chelating agents such as dicobalt edetate or
hydroxycobalamin. Dicobalt edetate is associated with
anaphylaxis and can produce hypertension, rhythm
Dries and Endorf Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2013, 21:31 Page 9 of 15
http://www.sjtrem.com/content/21/1/31changes or cobalt poisoning. At present, dicobalt edetate is
not available in the United States. It has been used in Great
Britain [57,64,65]. Hydroxycobalamin is an effective cyan-
ide antidote at a dose of 100 mg/kg. Unfortunately, in the
United States, hydroxycobalamin has been available at
1 mg/mL concentrations which limits usefulness as ap-
proximately 10 L of material would be needed to neutralize
a fatal cyanide dose [58,66]. The European approach to
cyanide poisoning is quite aggressive relative to the United
States. In Europe, 1 mg/L blood cyanide level is considered
significant or fatal. Hydroxycobalamin and dicobalt edetate
are used together to manage cyanide exposure in France
[58,65].
Cyanide antidotes have recently been reviewed by Hall
and coworkers. Scattered investigators in the United
States and French clinicians continue to study a variety
of agents available for management of this problem. A
number of agents are available with differing mechanisms
of action. Most of the clinical work, originating from fire-
fighters in Paris emphasizes the use of hydroxycobalamin
in smoke inhalation victims with high risk smoke expos-
ure. Various antidotes available for cyanide have varied tol-
erability and safety profiles. For example, dicobalt edetate
use is limited by toxicity concerns. Another cyanide anti-
dote used in Germany is 4-dimethylaminophenol. Like so-
dium nitrate and amyl nitrite, 4-dimethylaminophenol is
thought to neutralize cyanide by inducing methemoglobin.
Unfortunately, methemoglobin concentrations and tox-
icity can be significant with this agent. Use of dicobalt
edetate is limited by cobalt toxicity. Of studied agents,
hydroxycobalamin has the smallest toxicity profile apart
from allergic reactions. Because of a favorable side effect
profile, this agent has been used in small studies of
prehospital and empiric treatment of smoke exposure.
Hydroxycobalamin has rapid onset of action and neutral-
izes cyanide without interfering with cellular oxygen use.
At present, multiple investigators suggest that if employed,
hydroxycobalamin is the antidote of first resort in cyanide
exposure [67,68].
Hydroxycobalamin therapy has been used to prevent
cyanide toxicity in patients receiving intravenous nitro-
prusside and to treat toxic amblyopia and optic neuritis
caused by cyanide in tobacco smoke. In these applica-
tions, hydroxycobalamin is generally well tolerated but
may be associated with side effects of headache, allergic
reactions, skin and urine discoloration, hypertension or
reflex bradycardia [58,63,69]. Hyperbaric oxygen therapy
for cyanide has also been advocated. There is little ob-
jective data to support this application [58,70,71]. In
light of recent experience with hyperbaric oxygen in car-
bon monoxide toxicity, a role for this modality in cyan-
ide exposure is questionable [54].
In summary, the need for specific antidotes in cyanide
toxicity is unclear. Aggressive supportive therapy directedto restoration of cardiovascular function with provision of
supplemental oxygen augments hepatic clearance of cyan-
ide without specific antidotes and should be first line
treatment. Even with severe cyanide poisoning (blood
levels of 5–9 mg/L), after cyanide ingestion or smoke in-
halation, survival has been documented with aggressive
supportive therapy provided without cyanide antidotes
[58,72,73]. Another critical issue is the lack of a rapid
cyanide assay to document actual poisoning before anti-
dote administration is considered. If an accurate and
rapid cyanide assay is available, prospective studies can
then be designed to address the efficacy of various treat-
ment options.
Mechanical ventilation
There is no ideal respiratory support strategy for the pa-
tient with inhalation injury. Consensus recommendations
for mechanical ventilation continue to serve as general
guidelines [74]. Ventilator strategies must support oxygen-
ation and ventilation and reflect the experience of the
clinical team managing the patient. Limitation of pressure,
acceptance of permissive hypercapnia and strategies to
manage secretions are important. A significant number of
patients with smoke inhalation will develop pneumonia in
association with mechanical ventilation. Routine prevention
strategies include elevation of the head of the bed, frequent
position changes and oral care. Antibiotic prophylaxis has
no role and may increase infection rates. Extracorporeal
membrane oxygenation is perhaps the most dramatic res-
cue therapy and clearly not applicable as a standard therapy
at this time [75-77]. Simple strategies such as prone posi-
tioning are more practical in the hypoxic patient [78].
A number of ventilation modes have been recommended
for specific application to the patient with burn injury.
High Frequency Oscillatory Ventilation (HFOV) supports
the lung at a mean airway pressure above that used in con-
ventional ventilation. Oscillations may cause significant
pressure swings in the endotracheal tube while pressure
fluctuations are attenuated at the alveolar level. Small
studies suggest modest improvement in oxygenation with
HFOV over conventional ventilation strategies. Two recent
major trials do not support widespread use of HFOV
[79-81]. Airway Pressure Release Ventilation (APRV) uses
continuous positive airway pressure applied at a high level
with intermittent releases of airway pressure. Spontaneous
breathing during APRV more closely mimics gas distribu-
tion of normal breathing as opposed to mechanically
controlled breaths which produce a less physiologic gas
distribution. APRV has been used in a variety of critically
ill patients. A number of physiologic concerns remain to
be addressed before widespread application of APRV can
be recommended. For example, APRV can be associated
with significant elevation in mean airway pressure while
allowing lung collapse between episodes of continuous
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spontaneous breathing through an open ventilator circuit
may not be feasible. Finally, pulmonary transmural pres-
sure in APRV is not controlled and can be elevated signifi-
cantly. It appears that APRV can be used effectively by
clinicians familiar with its rationale and experienced in its
use. However, advantages of APRV over optimized conven-
tional ventilation have not been demonstrated and its ul-
timate role for management of patients with respiratory
failure has yet to be proven [82,83].
Noninvasive ventilation
Many studies report benefit with noninvasive ventilation
due to avoidance of endotracheal intubation and its as-
sociated complications. Without an endotracheal tube,
patients communicate more effectively, require less sed-
ation and are more comfortable. In addition, patients are
able to continue with standard oral care. Trauma associ-
ated with endotracheal tube insertion is avoided along
with sinusitis and impaired swallowing after extubation.
The benefit of noninvasive ventilation most discussed in
the literature is reduction in incidence, cost impact and
subsequent mortality of pneumonia [84,85].
A key component of the success of noninvasive venti-
lation has been selection of awake, cooperative, spontan-
eously breathing patients. These individuals must be
able to protect their airway. Hemodynamic or electrocar-
diographic instability or an unstable airway argue against
the use of noninvasive ventilation. The unconscious pa-
tient with significant facial injuries is not a candidate for
noninvasive ventilation. Further contraindications in-
clude compromised cough and the need for significant
clearance of secretions. High secretion load and facial
trauma are often seen with inhalation injury. Relative
contraindications include inability to fit and seal masks
and helmets secondary to injury or facial deformity
including facial hair. Uncooperative patients or those
who will not leave a mask in place, not cough when
prompted or are unable to remove the mask in the event
of emesis are not good candidates for noninvasive venti-
lation. If pressures used to ventilate the patient are
maintained below 30 mmHg, the closing pressure of the
lower esophageal sphincter should not be overcome and
aerophagia should be relatively uncommon. Finally, mor-
bid obesity is a relative contraindication due to increased
ventilator pressure requirements arising from body hab-
itus and weight of the chest wall or abdominal viscera
with the patient in bed [84].
The optimal time to consider use of noninvasive venti-
lation in the burn injured patient is unclear. Historically,
other patient groups have been treated with noninvasive
ventilation when signs of hypoxemia or hypercarbia are
present. Unlike other patient groups where respiratory
compromise is generally progressive, the insult faced bythe burn patient may be great in the initial hours after
injury during high volume fluid resuscitation. During
these initial hours, the risk of edema to burned and un-
burned tissue is signficiant. Noninvasive ventilation may
be considered as a prophylactic strategy during resusci-
tation in high risk patients even before frank signs of re-
spiratory insufficiency appear.
The most serious complication of noninvasive ventila-
tion is failure to recognize when this therapy is not
providing adequate ventilation, oxygenation or airway
support. Delayed intubation may cause continued deteri-
oration of the patient. Never lose a patient for failure to
intubate [84,85].
Ventilation
Patients with various forms of lung injury are now being
treated with ventilator strategies involving limitation of
minute ventilation through use of low tidal volumes
resulting in a tendency toward hypercapnia. While hy-
percapnia in the setting of acute lung injury may be
addressed in various ways, there is growing evidence that
acceptance may be a better alternative than aggressive
pursuit of normal carbon dioxide tension [86].
Airway pressures as low as 30 cmH2O have been asso-
ciated with lung injury in animal models. This pressure
corresponds with a normal static inflation pressure for
total lung capacity in humans. Thus, maintaining plateau
pressure <30 cmH2O is a reasonable approach to main-
tain aerated lung regions below normal maximum vol-
ume. This observation is important because high tidal
volume ventilation may be insensitive to loss of lung vol-
ume available for gas exchange due to the effects of in-
halation injury. Gattinoni and coworkers suggest that as
little as 20% of the lung may be aerated in patients with
severe respiratory failure. Thus, normal clinical tidal vol-
umes and airway pressures may be dangerous [87-89].
At present, there is insufficient data to suggest that hy-
percapnia should be independently induced outside the
context of a protective ventilation strategy. Ventilator
strategies involving hypercapnia are acceptable within
clinically reasonable hemodynamic bounds. Hypercapnic
acidosis has been demonstrated to increase cardiac output
in ARDS patients. Data from apnea tests and brain dead
patients suggests tolerance of a pH to 7.2 and a PCO2 >75
without hemodynamic consequences. At greater degrees
of hypercapnia and acidosis, hemodynamic instability may
become a limiting factor [89-92].
Oxygenation
Application of positive airway pressure is intended to re-
place or supplement respiratory muscle function and cor-
rect hypoxemia associated with alveolar hypoventilation.
Reversal of hypoxemia caused by intrapulmonary shunt
requires interventions that open lung units for gas
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injury, Positive End-Expiratory Pressure (PEEP) may in-
crease arterial oxygenation by increasing functional re-
sidual capacity, reducing venous add mixture, shifting
tidal volume to a more compliant portion of the pressure
volume curve and preventing loss of lung compliance dur-
ing mechanical ventilation. Work of breathing may also
be reduced [89,93-95].
PEEP also has a value beyond maintaining airway pa-
tency. In patients with obstructive respiratory disease,
lungs may fail to deflate to functional residual capacity
at end expiration. Alveolar pressure remains positive in
these individuals to an extent dependant on the volume
of trapped air. This phenomenon is referred to as “auto-
PEEP or extrinsic PEEP”. In the presence of auto-PEEP,
application of external PEEP is beneficial during spon-
taneous breathing as respiratory work is reduced and
during patient-triggered modes of ventilation where
breath initiation is supported. Optimal administration of
external PEEP in the setting of auto-PEEP reduces in-
spiratory muscle effort and improves patient ventilator
interaction [96].
PEEP has hemodynamic effects as well. Increased in-
trathoracic pressure causes a fall in cardiac output due
to reduced venous return. In patients with poor left
ventricular function, application of PEEP may serve to
decrease left ventricular afterload and improve left ven-
tricular performance. A small number of studies also
suggest that maintaining airway patency with PEEP may
facilitate clearance of secretions [94].
The general physiologic approach to hypoxemia in the
absence of confounding factors is to increase mean air-
way pressure. Elevation in PEEP, the immediate means
to this end, has been studied in a variety of multicenter
trials. In addition, application of PEEP in patients with
chronic obstructive pulmonary disease appears to improve
gas flow and mainten airway patency. In the chemical
pneumonitis and secretion accumulation, which accom-
panies smoke inhalation, airway pressure management
strategies may do more than optimize oxygenation; gas
flows and secretion movement can be favorably affected
[89,97].
In the 1980s, intrapulmonary percussion with diffusion
of oxygen via subtidal breaths and convective washout
of carbon dioxide was introduced by Dr. Forrest Bird.
This technology is now marketed as High Frequency
Percussive Ventilation (HFPV). The percussive nature of
this support enhances clearance of secretions. Cioffi and
others have reported improved outcomes with HFPV in
patients with inhalation injury for two decades [98-100].
As presently marketed, HFPV machines deliver high
frequency subtidal volume breaths followed by a passive
exhalation to a baseline preset continuous positive air-
way pressure. Respiration is time-cycled and pressurelimited with frequency, amplitude, inspiratory to expira-
tory time ratios and waveforms designed to maximize
ventilation and perfusion. Pulse frequency of subtidal
volume breaths can be varied to assist in providing max-
imal oxygenation. Typically rates of 500–600 are used
initially, but rates can be increased to a maximum of
700–750 if necessary. Amplitude of subtidal volume
breaths can also be adjusted to correlate with patient
peak inspiratory pressure. Interruption of percussive res-
piration permits passive CO2 elimination. A mandatory
respiratory rate is created by variable inspiratory and ex-
piratory times. Initially, a ventilator rate of approximately
one-half to two-thirds that of conventional respiration is
used for this background pressure. Ventilator variables are
subsequently adjusted based on patient response to
optimize gas exchange. Conventional ventilator modes are
typically used for weaning and extubation. More recent
experience with HFPV comes from Hall and coworkers at
the University of Texas Southwestern Medical Center.
Mortality benefit with HFPV was observed in patients
with burns <40% TBSA when comparison was made with
individuals receiving a conventional ventilation strategy
[98,100,101].
Medical adjuncts for treatment of smoke
inhalation
Current clinical treatment of inhalation injury remains
supportive. There has been little recent progress in ef-
fective clinical therapies, but there are many promising
experimental therapies not yet widely used in patients.
Unlike strategies directed specifically as antidotes for
products of combustion reviewed above, these interven-
tions address physiologic changes associated with smoke
inhalation.
Beta-agonists
As with other forms of acute lung injury, broncho-
constriction may further worsen already impaired gas
exchange in the injured alveoli. The use of inhaled
agents targeting beta-adrenoreceptors may help amelior-
ate this bronchoconstriction. Lange et al. studied nebu-
lized epinephrine in an ovine model of inhalation injury.
They divided 15 sheep into three groups: a sham-injury
group and two groups with actual inhalation injury, one
of which was treated with nebulized saline and the other
treated with nebulized epinephrine given every four
hours. They found that the nebulized epinephrine group
had decreases in airway pressures and increases in PaO2/
FiO2 ratios [102]. In another ovine study by Palmieri et al.,
continuous nebulized albuterol was given to a group of
sheep with a combined burn and inhalation injury and
compared to another group receiving nebulized saline.
The albuterol cohort had a decrease in airway pressures
and an improvement in PaO2/FiO2 ratio [103].
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There are two potential targets for modifying pulmonary
blood flow in inhalation injury. The first is diminishing
bronchial arterial blood flow and thus, decreasing the
flow of systemic inflammatory mediators to the lung.
Hamahata et al., again working with a sheep model, sur-
gically ligated the bronchial artery in one group of sheep.
They surgically exposed the bronchial artery in the
second group but left it intact rather than ligating the ar-
tery. They then exposed both groups to a combined
burn and smoke inhalation injury. This combined injury
increased bronchial blood flow, pulmonary edema, and
pulmonary dysfunction in both groups, but all these
changes were less severe in the group that had under-
gone bronchial artery ablation [104]. Building on these
initial findings, the same group then exposed the sheep
to the burn/smoke inhalation injury first, then used a
catheter to inject 70% ethanol into the bronchial artery
one hour after injury and compared it to groups with sa-
line injection and with no injury. Again, the injured
groups showed markedly worse blood gas analyses and
pulmonary mechanics, but those undergoing bronchial
artery sclerosis with ethanol had decreased bronchial
blood flow and less severe changes in their blood gases
and pulmonary mechanics [105].
Another promising modulator of pulmonary blood
flow is inhaled nitric oxide (NO). NO is a potent vaso-
dilator that when inhaled will be delivered selectively to
ventilated lung and vasodilate the capillaries serving
those areas. This results in decreased ventilation/perfu-
sion mismatch, decreased shunting, and decreased pul-
monary hypertension [106]. Enkhbataar et al. studied
inhaled NO in an ovine model compared to controls not
receiving NO. Their model of inhalation injury resulted
in increased lung water, increased pulmonary micro-
vascular resistance, and increase pulmonary artery pres-
sures. The NO group had less severe changes in these
variables when compared to the control group [107]. Qi
et al. studied inhaled NO in a canine model and found
that there was also less damage to the myocardium of
dogs receiving inhaled NO when compared to a control
group. The NO group also had improved cardiac energy
metabolism [108].
Anticoagulants
Significant airway obstruction is one of the hallmarks of
inhalation injury. Airway casts are formed by a combin-
ation of sloughed epithelial cells, mucus, inflammatory
cells, and fibrin. Fibrin in particular has been a target for
researchers to attempt to prevent formation of these air-
way casts.
Enkhbataar et al. used nebulized tissue plasminogen ac-
tivator (TPA) as a fibrinolytic agent in an experiment with
sheep subjected to a combined burn/smoke inhalationinjury. They found that TPA-treated sheep had less severe
impairment of pulmonary gas exchange, less pulmonary
edema, less of an increase in airway pressures, and less air-
way obstruction than control animals [109]. The same
group used a combination of aerosolized heparin and re-
combinant human antithrombin in another burn and
smoke inhalation ovine model. They found that the two
agents in combination resulted in better lung compliance,
less pulmonary edema, and less airway obstruction than
controls. Interestingly, neither agent used alone had the
same ameliorating effect [110].
Heparin in combination with N-acetylcysteine gained
widespread use after a study by Desai et al. showed de-
creased mortality in pediatric patients with inhalation in-
jury [111]. However, a subsequent retrospective review
by Holt et al. of 150 patients with inhalation injury showed
no significant improvement in clinical outcomes in pa-
tients treated with inhaled heparin and acetylcysteine
[112]. In addition, there has been at least one case report
of coagulopathy in a patient receiving aerosolized heparin
and acetylcysteine for inhalation injury [113].
Heparin was also combined with the anti-inflammatory
agent lisofylline in an ovine model by Tasaki et al. They
used three groups of sheep, one receiving nebulized saline
only, one getting nebulized heparin only, and the third re-
ceiving both nebulized heparin and intravenous lisofylline.
The combined heparin/lisofylline group had decreased
shunt and less of an increase in alveolar-arterial oxygen
tension gradient after a smoke inhalation injury. The
heparin-only group did not exhibit these same benefits
[114]. The efficacy of aerosolized heparin in the adult burn
and inhalation injury population is still unclear.
Antiinflammatory agents
Reducing the localized inflammatory response after in-
halation injury could theoretically decrease the mechan-
ical burden of biomaterials obstructing the airways, as
well as decreasing the long-term fibrotic reaction after
inhalation injury. There are a number of agents that
have been used to reduce inflammation, primarily in ani-
mal models.
Thromboxane A2 is an important inflammatory medi-
ator in lung injury, and inhibition of thromboxane syn-
thase has been shown to ameliorate lung injury in both
dogs and guinea pigs [115,116]. Westphal et al. used
OKY-046 (Ozagrel, 3-[4-(1H-imidazol-1ylmethyl)phenyl]-
2E-propanoic acid; Ono Pharmaceutical Co., Osaka,
Japan) as a thromboxane synthase inhibitor in a sheep
model of smoke inhalation injury. In a group of 16 sheep,
eight received the drug and eight received only the drug
delivery vehicle. They found that the treatment group had
decreased pulmonary thromboxane, and in turn had de-
creases in pulmonary vascular resistance and less of a de-
crease in cardiac output [117].
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inhalation injury. Scavengers of these reactive oxygen
radicals may help attenuate the pathologic inflammatory
response to smoke inhalation. Yamamoto et al. used
nebulized gamma-tocopherol (in ethanol) in six sheep
with severe burns and smoke inhalation and compared
them to five sheep with the nebulized ethanol alone.
They saw significant improvements in the P:F ratio of
the tocopherol group, as well as decreases in pulmonary
shunt and airway pressures [118].
The parasympathetic nervous system also contributes
to the physiologic response to airway injury by secreting
acetylcholine, which acts on muscarinic receptors to
constrict smooth muscle in the airways and stimulate ac-
tivity of submucosal glands. Inhibition of these muscar-
inic receptors blocks these effects as well as decreasing
production of inflammatory cytokines during lung injury
[119,120]. Jonkam et al. tested the muscarinic antagonist
tiotropium bromide in sheep with no injury, with smoke/
inhalation injury, and with smoke/inhalation injury receiv-
ing tiotropium bromide. Sheep with a combined burn and
inhalation injury showed increases in ventilatory pressures
and upper airway obstruction, as well as decreases in P:F
ratio. Treatment with this muscarinic receptor antagonist
resulted in a lesser degree of pathologic change in all these
variables [121].
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